TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10652956
Drug: Sequential estrogen/progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential estrogen/progestin (beta estradiol/norethisterone acetate)
Study: 4036269
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine against measles, mumps, and rubella (two doses: first at 18 months, second at 12 years)
Study: 27311730
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg IV days 1 and 15) and Everolimus (10 mg PO daily)
Study: 20231565
Drug: Salsalate 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate 3.0 g/d
Study: 26350812
Drug: Salsalate 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate 3.5 g/d
Study: 20231565
Drug: Salsalate 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate 4.0 g/d
Study: 16860051
Drug: 6% cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% cellulose sulfate gel
Study: 9231304
Drug: Clozapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (mean 324 mg daily)
Study: 9231304
Drug: Typical neuroleptics
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical neuroleptics (mean 465 mg chlorpromazine‐equivalents daily)
Study: 1806186
Drug: Anti-CD3 monoclonal
Normalized name: Anti-CD3
DrugBank: Muromonab (DB00075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD3 monoclonal antibodies
Study: 1806186
Drug: Anti-TNF monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-TNF monoclonal antibodies
Study: 27078990
Drug: Jianpi Liqi
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jianpi Liqi Yiliu Formula (JLYF) combined with cytokine‐induced killer (CIK) cells treatment
Study: 27078990
Drug: Cytokine‐induced killer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine‐induced killer (CIK) cells treatment
Study: 25263143
Drug: Extracorporeal shock-wave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal shock-wave therapy (1 application with 1000 impulses at 0.19 to 0.23 mJ per square millimeter)
Study: 22047909
Drug: Two portions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two portions of farmed salmon weekly (n=47)
Study: 7075642
Drug: Sotalol 160
Normalized name: sotalol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 160 mg
Study: 226565
Drug: Sotalol 320
Normalized name: sotalol 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 320 mg
Study: 17697301
Drug: Buccal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Buccal midazolam (0.2 mg/kg)
Study: 3058407
Drug: Postoperative iv-infusions
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative iv-infusions
Study: 21498062
Drug: IV tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tramadol 2.0 mg/kg
Study: 21498062
Drug: Tramadol infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol infiltration at trocar sites 2.0 mg/kg in 20 mL of 0.9% NaCl
Study: 18636958
Drug: Atazanavir 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 400 mg per day
Study: 18636958
Drug: Lopinavir-ritonavir 400
Normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir-ritonavir 400 mg and 100 mg twice per day
Study: 17030655
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid treatment (1.7 g of docosahexaenoic acid and 0.6 g of eicosapentaenoic acid daily)
Study: 9734743
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1.5 g/d)
Study: 8283290
Drug: L. GG
Normalized name: Lactobacillus rhamnosus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. GG yogurt (2 x 150 mL/d, containing 10(11) cfu/L of L. GG)
Study: 8283290
Drug: L. GG
Normalized name: Lactobacillus rhamnosus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. GG yogurt with rye fiber product (30 g/d, equivalent to 9 g fiber/d)
Study: 8283290
Drug: L. GG
Normalized name: Lactobacillus rhamnosus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. GG yogurt (with or without fiber)
Study: 2538676
Drug: Ketoconazole (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (1000 mg over 24 h) - short-term treatment
Study: 2538676
Drug: Ketoconazole (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (600 mg/die for 1 week up to 12 months) - long-term treatment
Study: 31977371
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 10 mg nalbuphine with 18 mL of 100 mg ropivacaine
Study: 31977371
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 20 mg nalbuphine with 18 mL of 100 mg ropivacaine
Study: 31977371
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of normal saline with 18 mL of 100 mg ropivacaine
Study: 31367958
Drug: Hypoglycaemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemic clamp (plasma glucose 3.0 ± 0.2 mmol/l)
Study: 31367958
Drug: Euglycaemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemic clamp (plasma glucose 6.0 ± 0.2 mmol/l)
Study: 26561621
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate intake (median: 238 g/d)
Study: 26561621
Drug: Low carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low carbohydrate intake (median: 188 g/d)
Study: 19361304
Drug: Subunit vaccine
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccine (among HIV-infected patients)
Study: 19361304
Drug: Virosomal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosomal vaccine (among HIV-infected patients)
Study: 19361304
Drug: Subunit vaccine
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccine (among renal transplant patients)
Study: 19361304
Drug: Virosomal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosomal vaccine (among renal transplant patients)
Study: 16625311
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of solifenacin once daily
Study: 16625311
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of solifenacin once daily
Study: 16997737
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg imMP with placebo tablets
Study: 16997737
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection with prednisolone 30 mg daily
Study: 11704123
Drug: Micronized 17beta‐E(2),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized 17beta‐E(2), 2 mg/day orally (cycle days 1 to 28)
Study: 11704123
Drug: Micronized 17beta‐E(2),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized 17beta‐E(2), administered vaginally (cycle days 1 to 28)
Study: 8106156
Drug: 175 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 175 mg/m2 TAXOL administered by 3-h infusion
Study: 8106156
Drug: 135 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg/m2 TAXOL administered by 3-h infusion
Study: 8106156
Drug: 175 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 175 mg/m2 TAXOL administered by 24-h infusion
Study: 8106156
Drug: 135 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg/m2 TAXOL administered by 24-h infusion
Study: 27697605
Drug: i-gel supraglottic
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel supraglottic airway device
Study: 28653869
Drug: Neuromuscular exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular exercise (NEMEX) program; 8-week, twice-weekly program consisting of 11 exercises with 3 to 4 levels of difficulty
Study: 26363899
Drug: Inclacumab 20
Normalized name: Inclacumab
DrugBank: Inclacumab (DB12246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclacumab 20 mg/kg
Study: 23500230
Drug: Inclacumab 5
Normalized name: Inclacumab
DrugBank: Inclacumab (DB12246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclacumab 5 mg/kg
Study: 18212288
Drug: Gadoversetamide doses
Normalized name: Gadoversetamide
DrugBank: Gadoversetamide (DB00538)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gadoversetamide doses > or = 0.2 mmol/kg
Study: 11303311
Drug: Glucocorticosteroids (gcs),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticosteroids (gcs), total dose equivalent to prednisone 7.4 ± 8.3 g
Study: 11303311
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with glucocorticosteroids (gcs)
Study: 8619449
Drug: Pyronaridine 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyronaridine 1,200 mg over a three-day period (Group I)
Study: 8619449
Drug: Pyronaridine 1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyronaridine 1,800 mg over a five-day period (Group II)
Study: 8619449
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro drug sensitivity tests
Study: 1463951
Drug: Paracetamol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol plus unwrapping
Study: 6363434
Drug: Dihydrotestosterone (DHT)
Normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Stanolone acetate (DB13951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrotestosterone (DHT) 125 mg twice daily for 10 days
Study: 31688451
Drug: PF-02545920 5
Normalized name: haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-02545920 5 mg Q12H
Study: 31688451
Drug: PF-02545920 15
Normalized name: PF-04360365
DrugBank: Ponezumab (DB15135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-02545920 15 mg Q12H
Study: 31688451
Drug: Risperidone 3
Normalized name: risperidone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 3 mg Q12H
Study: 26154787
Drug: Guselkumab 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 50 mg
Study: 22291101
Drug: Zoster vaccine
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoster vaccine (ZV) (Zostavax; Merck)
Study: 11856079
Drug: Balsalazide, 6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide, 6.75 g daily
Study: 11856079
Drug: Sulfasalazine, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine, 3 g daily
Study: 8134222
Drug: Acetaminophen (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (15 mg/kg per dose, 0.15 mL/kg per dose) every 6 hours for 24 hours
Study: 8134222
Drug: Placebo (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.15 mL/kg per dose) every 6 hours for 24 hours
Study: 8134222
Drug: Acetaminophen and
Normalized name: Acetaminophen and Aspirin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen and Placebo (both groups)
Study: 1168110
Drug: Hog mucosal
Normalized name: hog epithelia extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hog mucosal heparin
Study: 31135550
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (enoxaparin 40 mg or dalteparin 5000 IUs daily)
Study: 31135550
Drug: Chemoprophylaxis (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoprophylaxis (various types including aspirin and warfarin)
Study: 28406882
Drug: Educational support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational support (ES) group - additional polysomnography chart viewing from both diagnostic and titration nights
Study: 28406882
Drug: Standard support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard support (SS) group - general information about OSA and PAP treatment at baseline
Study: 21749677
Drug: MDFT (Multidimensional
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDFT (Multidimensional Family Therapy)
Study: 19459997
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 60 mg extended release (XR)
Study: 16702250
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care with 2-L supplemental oxygen via nasal cannula and capnography monitoring for >60 seconds
Study: 10722180
Drug: Quetiapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (mean total daily dose 455 mg)
Study: 10722180
Drug: Haloperidol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (mean total daily dose 8 mg)
Study: 4040552
Drug: Metoclopramide (IV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (IV, 2 mg/kg over 15 minutes, given 30 minutes before, 30 minutes after, and three hours after cisplatin)
Study: 24722500
Drug: Imeglimin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imeglimin (1,500 mg b.i.d.)
Study: 17522765
Drug: 0.2% glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% glyceryl trinitrate (GTN) ointment
Study: 19403710
Drug: Iron deficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron deficiency (plasma ferritin <12 microg/L or transferrin receptor >4.4 mg/L)
Study: 19403710
Drug: Anemia (hemoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemia (hemoglobin <120 g/L)
Study: 19403710
Drug: Folate deficiency
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate deficiency (plasma folate <or=10 nmol/L)
Study: 11442213
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and chloroquine treatment for symptomatic malaria infection
Study: 11442213
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and monthly presumptive treatment with sulfamethoxazole-pyrimethamine (SP)
Study: 11442213
Drug: Monthly SP
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly SP and thrice‐weekly vitamins A and C (VAC)
Study: 7664433
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg BID, n = 33)
Study: 2666040
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg acyclovir by mouth, twice daily, for 12 weeks
Study: 2666040
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo by mouth, twice daily, for 12 weeks
Study: 25734713
Drug: L‐PRF (Leukocyte‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐PRF (Leukocyte‐ and platelet‐rich fibrin)
Study: 22448476
Drug: Panavir added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Panavir added to combined treatment
Study: 16317106
Drug: Bitter Orange
Normalized name: BITTER ORANGE
DrugBank: Citrus aurantium fruit (DB16598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter Orange (900 mg dietary supplement extract standardized to 6% synephrine)
Study: 14744573
Drug: Flumazenil (1
Normalized name: Flumazenil (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1 mg i.v. loading dose followed by 0.5 mg i.v. infusion over 30 min)
Study: 11384023
Drug: 3% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% prilocaine with 0.03IU/ml felypressin
Study: 8499580
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg fluvoxamine maleate
Study: 8499580
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg fluvoxamine maleate
Study: 8499580
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg fluvoxamine maleate
Study: 8499580
Drug: Fluvoxamine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (all doses)
Study: 6356306
Drug: Fluocortin butylester
Normalized name: fluocortin
DrugBank: Fluocortin (DB13223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortin butylester (FCB) administered by inhalation through a special inhalator (Rhinolator) for three weeks
Study: 24682421
Drug: Clofarabine 5×10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofarabine 5×10 mg/m²/day
Study: 24682421
Drug: Clofarabine 15
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine 15 mg/m²/day
Study: 24682421
Drug: Clofarabine 10
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine 10 mg/m²/day
Study: 24682421
Drug: Clofarabine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofarabine (various doses)
Study: 22437295
Drug: FJ injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: FJ injections (FJI)
Study: 19491895
Drug: XELOX (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX (capecitabine plus oxaliplatin) as first-line chemotherapy
Study: 19491895
Drug: XELOX (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX (capecitabine plus oxaliplatin) as second-line chemotherapy
Study: 17453864
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch (300 mug/24 h)
Study: 10779453
Drug: beta-radiation therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-radiation therapy with 90-yttrium, 20.6 Gy dose at 1.0 mm from the balloon surface
Study: 30010509
Drug: Higher intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher intensity and dose exercise programs (5 days/week for four weeks)
Study: 30010509
Drug: Usual inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual inpatient physical therapy care
Study: 30010509
Drug: Higher intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher intensity and dose exercise programs
Study: 28005247
Drug: Low-dose capecitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose capecitabine plus docetaxel (capecitabine 825 mg/m2 twice daily, days 1-14; docetaxel 60 mg/m2, day 1 every 3 weeks)
Study: 28005247
Drug: Single-agent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent docetaxel (70 mg/m2, day 1 every 3 weeks)
Study: 28005247
Drug: Low-dose capecitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose capecitabine plus docetaxel
Study: 26227087
Drug: FDC fenofibrate/simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC fenofibrate/simvastatin 145/20 mg or 145/40 mg
Study: 9610957
Drug: plasminogen activator
Normalized name: Plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: plasminogen activator inhibitor antigen
Study: 29667153
Drug: Rehab +
Normalized name: Foot Rehab Pain & Moisture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehab + EAAs (8 g/day)
Study: 23748568
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (open reduction and stabilization with screws and wires, n=29)
Study: 4599858
Drug: Ampicillin plus
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin plus probenecid (3.5 g ampicillin with 1.0 g probenecid)
Study: 4599858
Drug: Amoxicillin alone
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin alone (3.0 g)
Study: 18045731
Drug: Carboxyaminoimidazole (CAI)
Normalized name: Carboxyamidotriazole
DrugBank: Carboxyamidotriazole (DB11960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxyaminoimidazole (CAI) 250mg daily
Study: 8773867
Drug: Epidural hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural hydromorphone (0.6 mg)
Study: 1299733
Drug: Peri-operative antibiotics
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peri-operative antibiotics for clean-contaminated (class B) and contaminated (class C) cases only.
Study: 1299733
Drug: Routine group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine group received prolonged antibiotics.
Study: 1299733
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics for clean cases (class A).
Study: 6380856
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg orally 4 times a day during hospitalization + Metoprolol 15 mg intravenously 20 min after initial administration, then 50 mg 4 times a day
Study: 6380856
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Metoprolol 15 mg intravenously 20 min after initial administration, then 50 mg 4 times a day
Study: 28921723
Drug: Prophylactic cefalexin
Normalized name: cefalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic cefalexin (22 mg/kg twice daily)
Study: 24716713
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 4 Joules
Study: 24716713
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 6 Joules
Study: 24716713
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 8 Joules
Study: 24716713
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) protocol that achieved the best muscle performance in phase 1
Study: 18400585
Drug: Cetrorelix 0.25
Normalized name: cetrorelix 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix 0.25 mg
Study: 18400585
Drug: Cetrorelix 0.2
Normalized name: cetrorelix 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix 0.2 mg
Study: 18400585
Drug: Cetrorelix 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix 0.15 mg
Study: 18400585
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (LA) 0.5 mg/day
Study: 18400585
Drug: Single half-dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single half-dose LA depot 1.88 mg
Study: 12795797
Drug: 0.5% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% chlorhexidine gel